EOFLOWLtd (KOSDAQ:A294090) - Share price, News & Analysis

A294090 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

A294090 Stock Overview

EOFLOW Co.,Ltd. develops and provides drug delivery solutions.

Rewards

Revenue grew by 3101.5% over the past year

Risk Analysis

Makes less than USD$1m in revenue (₩693M)

Has less than 1 year of cash runway

Less than 3 years of financial data is available

Shareholders have been diluted in the past year

Price History & Performance

Summary of all time highs, changes and price drops for EOFLOWLtd
Historical stock prices
Current Share Price	₩21,500.00
52 Week High	₩34,500.00
52 Week Low	₩18,900.00
Beta	0
1 Month Change	-8.12%
3 Month Change	2.14%
1 Year Change	-25.99%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	115.00%

Shareholder Returns

	A294090	KR Medical Equipment	KR Market
7D	-5.1%	-2.5%	-1.9%
1Y	-26.0%	-9.9%	-15.5%

Return vs Industry: A294090 underperformed the KR Medical Equipment industry which returned -9.9% over the past year.

Return vs Market: A294090 underperformed the KR Market which returned -15.5% over the past year.

Price Volatility

Is A294090's price volatile compared to industry and market?
A294090 volatility
A294090 Average Weekly Movement	5.2%
Medical Equipment Industry Average Movement	5.6%
Market Average Movement	5.5%
10% most volatile stocks in KR Market	10.6%
10% least volatile stocks in KR Market	3.2%

Stable Share Price: A294090 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: A294090's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2011	110	Jesse Kim	https://www.eoflow.com

EOFLOW Co.,Ltd. develops and provides drug delivery solutions. The company offers EOPatch, a wearable insulin pump system.

EOFLOWLtd Fundamentals Summary

How do EOFLOWLtd's earnings and revenue compare to its market cap?
A294090 fundamental statistics
Market Cap	₩647.01b
Earnings (TTM)	-₩29.75b
Revenue (TTM)	₩693.27m

933.3x

P/S Ratio

-21.7x

P/E Ratio

Is A294090 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A294090 income statement (TTM)
Revenue	₩693.27m
Cost of Revenue	₩3.35b
Gross Profit	-₩2.66b
Other Expenses	₩27.09b
Earnings	-₩29.75b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-988.58
Gross Margin	-383.92%
Net Profit Margin	-4,291.24%
Debt/Equity Ratio	192.8%

How did A294090 perform over the long term?

See historical performance and comparison

Valuation

Is EOFLOWLtd undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

35.46x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A294090's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A294090's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: A294090 is unprofitable, so we can't compare its PE Ratio to the KR Medical Equipment industry average.

PE vs Market: A294090 is unprofitable, so we can't compare its PE Ratio to the KR market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A294090's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: A294090 is overvalued based on its PB Ratio (35.5x) compared to the KR Medical Equipment industry average (2.6x).

Future Growth

How is EOFLOWLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

6.6%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as EOFLOWLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has EOFLOWLtd performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-51.4%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: A294090 is currently unprofitable.

Growing Profit Margin: A294090 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Unable to establish if A294090's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare A294090's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A294090 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (30.5%).

Return on Equity

High ROE: A294090 has a negative Return on Equity (-158.52%), as it is currently unprofitable.

Financial Health

How is EOFLOWLtd's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A294090's short term assets (₩37.3B) exceed its short term liabilities (₩3.3B).

Long Term Liabilities: A294090's short term assets (₩37.3B) do not cover its long term liabilities (₩40.5B).

Debt to Equity History and Analysis

Debt Level: A294090's net debt to equity ratio (12.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if A294090's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A294090 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: A294090 has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 101.6% each year.

Dividend

What is EOFLOWLtd current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A294090's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A294090's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A294090's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A294090's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A294090 has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Healthcare industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Jesse Kim (60 yo)

no data

Tenure

Mr. Jaejin Kim, also known as Jesse serves as Chief Executive Officer at EOFLOW Co.,Ltd.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/09 00:00
End of Day Share Price	2022/05/06 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31